The ovarian cancer oncobiome
Metrics: PDF 166 views | HTML 59 views | ?
Sagarika Banerjee1, Tian Tian2, Zhi Wei2, NatalieShih3, Michael D. Feldman3, George Coukos4, James C. Alwine5, Erle S. Robertson1
1Departments of Otorhinolaryngology-Head and Neck surgery, and Microbiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania 19104, United States of America
2Department of Computer Science, New Jersey Institute of Technology, New Jersey 07102, United States of America
3Department of Pathology and Laboratory Medicine, University of Pennsylvania 19104, Philadelphia, Pennsylvania, United States of America
4Ludwig Institute for Cancer Research, University of Lausanne Branch and Department of Oncology, CHUV, Lausanne, Switzerland
5Department of Cancer Biology, University of Pennsylvania, Philadelphia, Pennsylvania 19104, United States of America
Erle S. Robertson, email: email@example.com
Keywords: oncobiome, microbiome, ovarian cancer, pathochip, next generation sequencing
Received: August 15, 2016 Accepted: March 08, 2017 Published: March 30, 2017
Humans and other mammals are colonized by microbial agents across the kingdom which can represent a unique microbiome pattern. Dysbiosis of the microbiome has been associated with pathology including cancer. We have identified a microbiome signature unique to ovarian cancers, one of the most lethal malignancies of the female reproductive system, primarily because of its asymptomatic nature during the early stages in development. We screened ovarian cancer samples along with matched, and non-matched control samples using our pan-pathogen array (PathoChip), combined with capture-next generation sequencing. The results show a distinct group of viral, bacterial, fungal and parasitic signatures of high significance in ovarian cases. Further analysis shows specific viral integration sites within the host genome of tumor samples, which may contribute to the carcinogenic process. The ovarian cancer microbiome signature provides insights for the development of targeted therapeutics against ovarian cancers.
Michael D Feldman
James C. Alwine
Erle S. Robertson
Primary Contact _
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.